Basilea Pharmaceutica Sustainability Profile
Basilea Pharmaceutica AG, commonly referred to as Basilea, is a Swiss biopharmaceutical company headquartered in Basel, Switzerland. Founded in 2000, Basilea focuses on the development and commercialisation of innovative therapies for oncology and infectious diseases. The company has made significant strides in the pharmaceutical industry, particularly with its core products, which include advanced treatments for resistant infections and cancer. Basilea's unique approach combines cutting-edge research with a commitment to addressing unmet medical needs, positioning it as a key player in the global biopharmaceutical landscape. With a strong presence in Europe and North America, Basilea has achieved notable milestones, including successful product launches and strategic partnerships that enhance its market position. The company's dedication to innovation and patient care continues to drive its growth and reputation in the industry.
DitchCarbon Score
How does Basilea Pharmaceutica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Basilea Pharmaceutica's score of 28 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Basilea Pharmaceutica's reported carbon emissions
Basilea Pharmaceutica, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards carbon neutrality or emissions reduction initiatives at this time. As there is no inherited emissions data from a parent company or related organisation, all information is based solely on Basilea Pharmaceutica's own disclosures. The absence of specific climate commitments or targets may reflect a broader industry context where many pharmaceutical companies are increasingly focusing on sustainability and climate action, but Basilea Pharmaceutica has yet to publicly align with such initiatives.
How Carbon Intensive is Basilea Pharmaceutica's Industry?
How Carbon Intensive is Basilea Pharmaceutica's Location?
Basilea Pharmaceutica's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Basilea Pharmaceutica has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
